Navigation Links
Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers

- Study Identifies Novel Biomarkers Displaying 90% Sensitivity in Breast

Cancer -

ST. LOUIS, Dec. 20 /PRNewswire/ -- Orion Genomics announced today the discovery and validation of the most frequent DNA alterations detected in breast cancer to date. The results of a genome-wide analysis of DNA methylation appeared in PLoS ONE. The study entitled, "Identification of Novel High-Frequency DNA Methylation Changes in Breast Cancer" found more than 50 novel biomarkers, which were subsequently validated in up to 230 independent patient samples.

"Our study identified novel biomarkers that were individually capable of distinguishing early stage ductal breast cancer from normal and benign breast tissue," commented Jared Ordway, Ph.D., Director of Research and Development at Orion Genomics. "We are very excited about the potential of these findings as these biomarkers may be critical in the development of molecular diagnostics for the early detection of breast cancer."

Researchers applied a patented microarray-based approach to map tumor associated changes in DNA methylation, alterations that can affect normal gene expression. A single locus associated with the GHSR gene was the most powerful biomarker in the study, with a clinical sensitivity of 90% and a specificity of 96% for infiltrating ductal breast carcinoma. In addition to identifying biomarkers that might aid in the detection of breast cancer, the research revealed insights into the molecular mechanism of tumor development, which may lead to advances in breast cancer treatment.

"Twelve of our more than fifty breast cancer biomarkers exceeded the highest sensitivity previously reported for the stratification of tumor and normal tissue," added Nathan D. Lakey, President and CEO of Orion Genomics. "These results validate our biomarker discovery platform and our product pipeline, which is focused on breast, lung and ovarian cancer diagnostics."

About Orion Genomics

Orion Genomics, the Second Code biotechnology company, develops genomic research tools and molecular diagnostic products to detect cancer at its earliest stages and to aid in appropriate therapy selection. The company has active biomarker discovery programs in cancers of the bladder, breast, lung, ovaries and colon. Orion Genomics is located in the Center for Emerging Technologies in St. Louis. For more information, visit

SOURCE Orion Genomics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
(Date:10/13/2015)... , October 14, 2015 ... The Global Nocturia Clinical Trials Review, H2, ... of worldwide Nocturia scenario, top line data ... as information on companies and institutes involved. ... . --> ...
(Date:10/13/2015)... NEW YORK , Oct. 13, 2015 ... been filed against Amicus Therapeutics, Inc. ("Amicus" or the ... action, filed in United States District Court, District of ... of a class consisting of all persons or entities ... October 1, 2015 inclusive (the "Class Period"). This class action ...
(Date:10/13/2015)... 13, 2015  The Alliance for Safe Biologic ... survey of 401 U.S. pharmacists showing strong support for ... for more transparency in labeling. Michael Reilly ... "This survey reinforces what ASBM has been hearing ... it clear that they prefer distinguishable names and more ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... celebrating the opening of the Integrative Biosciences Center (IBio), a $93 million facility ... A grand opening celebration will be held at 10:30 a.m. Wednesday, Oct. 14, ...
(Date:10/13/2015)... ... October 14, 2015 , ... The ... of needle-placement technique in radiofrequency ablation for treatment of lumbar facet arthropathy ”. ... in nature, highlights the importance of anatomically correct needle placement technique for lumbar ...
(Date:10/13/2015)... ... October 13, 2015 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... A Commitment to Cure last night at the Mandarin Oriental in New York ...
(Date:10/13/2015)... ... 13, 2015 , ... “Women have 2 questions when they find out they ... second is, “Will I lose my hair?’” , Carly Klein is the Founder of ... medical professionals to develop personalized hair loss treatment plans. With 10 years’ experience in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Though trick-or-treating remains ... confines of their home. Whether it's making fun pre or post trick-or-treat snacks ... Florida Dairy Farmers. , Recipe 1: Green Chile Queso Dip with Sriacha ...
Breaking Medicine News(10 mins):